Literature DB >> 3481250

CA 125 in the serum and tissue of patients with gynecological disease.

L C Fuith1, G Daxenbichler, O Dapunt.   

Abstract

Serum levels of CA 125 were determined in 239 patients suffering from gynecological malignancies. The upper limit for normal was 35 U/ml. Raised levels were found in 82% of patients with primary ovarian carcinoma, and in 29% of those with benign ovarian tumors. The values from patients with ovarian carcinomas in partial or complete remission were compared with those from patients with progressive disease. The former group had elevated levels in 19% compared to 89% in the latter group. Fifty-four percent of the values in progressive cervical carcinoma and 41% of the levels in progressive endometrial carcinoma were greater than 35 U/ml. High CA 125 levels were found in the cytosol of placenta, ovarian carcinoma, cervical carcinoma, and in ascitic fluid; correlation with serum levels was satisfactory. Even though CA 125 is of limited specificity for ovarian cancer, serum levels are important for follow up care and for the early detection of recurrences.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481250     DOI: 10.1007/BF00931312

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  11 in total

1.  CA125 seric levels in non malignant pathologies.

Authors:  A Ruibal; G Encabo; E Martinéz-Miralles; C Murcia; J A Capdevila; A Salgado; J M Martinéz-Vasquéz
Journal:  Bull Cancer       Date:  1984       Impact factor: 1.276

2.  Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.

Authors:  F Pansini; A Bellinazzi; V Rainaldi; M Santoiemma; B Lenzi; M Jacobs; G Mollica; B Bagni
Journal:  Gynecol Obstet Invest       Date:  1986       Impact factor: 2.031

3.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

4.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.

Authors:  J M Niloff; R C Bast; E M Schaetzl; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1985-04-01       Impact factor: 8.661

5.  Longitudinal study of CEA and CA125 in ovarian cancer.

Authors:  P A Brioschi; P Bischof; C Rapin; M De Roten; O Irion; F Krauer
Journal:  Gynecol Oncol       Date:  1985-05       Impact factor: 5.482

6.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

7.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

8.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

9.  Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix.

Authors:  J M Niloff; T L Klug; E Schaetzl; V R Zurawski; R C Knapp; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1984-04-15       Impact factor: 8.661

10.  Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.

Authors:  R C Bast; T L Klug; E Schaetzl; P Lavin; J M Niloff; T F Greber; V R Zurawski; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1984-07-01       Impact factor: 8.661

View more
  7 in total

1.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Authors:  Richard G Moore; Michael Craig Miller; Margaret M Steinhoff; Steven J Skates; Karen H Lu; Geralyn Lambert-Messerlian; Robert C Bast
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

3.  Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.

Authors:  J Brökelmann; A Bockisch; J Vogel; J Reinsberg; P Oehr; H J Biersack; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and Fallopian tube. II. Immunoradiometric determination in secretions, tissue extracts and serum.

Authors:  G Crombach; A Scharl; H Würz
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

5.  Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.

Authors:  M M Uttenreuther-Fischer; H Feistel; F Wolf; W Jäger
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Authors:  Raffit Hassan; Charles Schweizer; Kun F Lu; Barbara Schuler; Alan T Remaley; Susan C Weil; Ira Pastan
Journal:  Lung Cancer       Date:  2009-09-09       Impact factor: 5.705

7.  Cytokines, chemokines, and chemokine receptors quantitative expressions in patients with ovarian cancer.

Authors:  Somayeh Rezaeifard; Mahboobeh Razmkhah; Minoo Robati; Mozhdeh Momtahan; Abbas Ghaderi
Journal:  Iran J Med Sci       Date:  2015-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.